Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

被引：0

作者：

Monica N. Khattak

Anna M. Chichura

Julie E. Lang

机构：

[1] Cleveland Clinic Foundation,Division of Breast Services

来源：

Annals of Surgical Oncology | 2024年 / 31卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

This ASO perspective reviews the findings of a randomized, phase II clinical trial evaluating adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel and trastuzumab (TH) in stage I human epidermal growth factor receptor 2-positive breast cancer, as reported recently by the ATEMPT trial investigators. Patients treated with T-DM1 had better disease-free survival but did not have fewer treatment toxicities. The T-DM1-treated group had higher rates of treatment discontinuations, therefore long-term follow-up will be required to evaluate survival differences between T-DM1 and TH.

引用

页码：1423 / 1427

页数：4

共 50 条

[21] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [J].

Cochereau, D. ;

Cottu, P. .

ONCOLOGIE, 2015, 17 (04) :194-196

[22] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer [J].

不详 .

GYNAKOLOGE, 2016, 49 (08) :558-558

[23] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer [J].

Tolaney, Sara M. ;

Barry, William T. ;

Dang, Chau T. ;

Yardley, Denise A. ;

Moy, Beverly ;

Marcom, P. Kelly ;

Albain, Kathy S. ;

Rugo, Hope S. ;

Ellis, Matthew ;

Shapira, Iuliana ;

Wolff, Antonio C. ;

Carey, Lisa A. ;

Overmoyer, Beth A. ;

Partridge, Ann H. ;

Guo, Hao ;

Hudis, Clifford A. ;

Krop, Ian E. ;

Burstein, Harold J. ;

Winer, Eric P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02) :134-141

[24] Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT [J].

Tarantino, Paolo ;

Tayob, Nabihah ;

Villacampa, Guillermo ;

Dang, Chau ;

Yardley, Denise A. ;

Isakoff, Steven J. ;

Valero, Vicente ;

Faggen, Meredith ;

Mulvey, Therese ;

Bose, Ron ;

Weckstein, Douglas ;

Wolff, Antonio C. ;

Reeder-Hayes, Katherine ;

Rugo, Hope S. ;

Ramaswamy, Bhuvaneswari ;

Zuckerman, Dan ;

Hart, Lowell ;

Gadi, Vijayakrishna K. ;

Constantine, Michael ;

Cheng, Kit ;

Garrett, Audrey Merrill ;

Marcom, P. Kelly ;

Albain, Kathy ;

Defusco, Patricia ;

Tung, Nadine ;

Ardman, Blair ;

Nanda, Rita ;

Jankowitz, Rachel C. ;

Rimawi, Mothaffar ;

Abramson, Vandana ;

Pohlmann, Paula R. ;

Van Poznak, Catherine ;

Forero-Torres, Andres ;

Liu, Minetta C. ;

Ruddy, Kathryn J. ;

Waks, Adrienne G. ;

Demeo, Michelle ;

Burstein, Harold J. ;

Partridge, Ann H. ;

Dell'Orto, Patrizia ;

Russo, Leila ;

Krause, Emma ;

Newhouse, Daniel J. ;

Kurt, Busem Binboga ;

Mittendorf, Elizabeth A. ;

Schneider, Bryan ;

Prat, Aleix ;

Winer, Eric P. ;

Krop, Ian E. ;

Tolaney, Sara M. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (31) :3652-3665

[25] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer [J].

Phillips, Gail .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250

[26] A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL [J].

Silva Miguel, L. ;

Pinheiro, B. ;

Lopes, R. ;

Revil, C. ;

Monteiro, I ;

Borges, M. .

VALUE IN HEALTH, 2022, 25 (01) :S69-S70

[27] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer [J].

Mano, Max S. .

FUTURE ONCOLOGY, 2020, 16 (32) :2595-2609

[28] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine [J].

Sadeghi, Saeed ;

Olevsky, Olga ;

Hurvitz, Sara A. .

PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 :329-338

[29] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine [J].

Recondo, Gonzalo, Jr. ;

de la Vega, Maximo ;

Galanternik, Fernando ;

Diaz-Canton, Enrique ;

Amadeo Leone, Bernardo ;

Leone, Jose Pablo .

CANCER MANAGEMENT AND RESEARCH, 2016, 8 :57-65

[30] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer [J].

Elsada, Ahmed ;

Doss, Sally ;

Robertson, Janet ;

Adam, E. Jane .

LANCET ONCOLOGY, 2016, 17 (02) :143-144

← 1 2 3 4 5 →